In Alagille syndrome…

AIM TO DITCH THE ITCH

FDA APPROVED:

Once-daily LIVMARLI is the first and only FDA-approved medicine for cholestatic pruritus (itch) in patients with Alagille syndrome who are 1 year of age and older.

Cost Support
Cost Support »

Financial support options that may help with out-of-pocket costs for LIVMARLI are available.

Find Out More
Improvements In Itch
Improvements in Itch »

In a clinical study, many patients taking LIVMARLI experienced significantly less itchiness.

See the Results
Once-daily Dosing
Once-daily Dosing »

LIVMARLI is a once-daily oral medicine that’s taken 30 minutes before the first meal of the day.

Learn How to Take LIVMARLI
Lightning bolt sticker

WELCOME TO THE LIVER LEAGUE INFORMATION BOOTH

Stay in the Know

To receive more information about LIVMARLI as it becomes available, please fill out the form below.

*Required.

By completing this form, you agree to our Terms of Use and Privacy Policy.

HOORAY!
Your sign-up was successful!

Be on the lookout for a welcome email from Mirum soon. Make sure to add livmarli-info@mirumpharma.com to your address book so that our emails go directly to your inbox.

YIKES!
We're having some connection trouble.

Refresh the page and try submitting your form again.

Note: This issue may occur if your email is already registered. Please check your inbox and spam folder to make sure you're receiving information. If the issue persists, please contact us.

OOPS!
Looks like this email is already registered.

Please check your inbox and spam folder to make sure you're receiving information.

Liver League kids
expand btn collapse btn

Indication

LIVMARLI is a prescription medicine used to treat cholestatic pruritus (itch) in patients with Alagille syndrome 1 year of age and older. It is not known if LIVMARLI is safe and effective in children under 1 year of age or in adults 65 years and older.

Important Safety Information

What are the possible side effects 
of LIVMARLI?

LIVMARLI can cause serious side effects, including:

Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your health care provider should do blood tests before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:

  • nausea or vomiting
  • skin or the white part of the eye turns yellow
  • dark or brown urine
  • pain on the right side of the stomach (abdomen)
  • loss of appetite

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your health care provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat-Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamins A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment.

Other common side effects reported during treatment were bone fractures and gastrointestinal bleeding.

Tell your health care provider about all medicines that you take. LIVMARLI may affect the way some other medicines work, and some other medicines may affect the way LIVMARLI works. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI.

LIVMARLI is taken by mouth, 1 time each day, 30 minutes before the first meal of the day. Be sure to use the provided oral dosing dispenser to accurately measure the dose of medicine.

These are not all of the possible side effects of LIVMARLI. Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see Patient Information: English | Español